Research output per year
Research output per year
Fingerprint
Dive into the research topics where Jens Tijtgat is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
371P - Low-dose bevacizumab for the treatment of focal post-radiation necrosis of the brain
Tijtgat, J., Schwarze, J. K. & Awada, G., 16 Sep 2021.Research output: Unpublished contribution to conference › Poster
-
A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab
Awada, G., Jansen, Y., Schwarze, J. K., Tijtgat, J., Hellinckx, L., Gondry, O., Vermeulen, S., Warren, S., Schats, K., van Dam, P-J., Kockx, M., Keyaerts, M., Everaert, H., Seremet, T., Rogiers, A. & Neyns, B., 2 Jan 2021, In : Cancers. 13, 2, p. 1-18 18 p., 168.Research output: Contribution to journal › Article
1 Citation (Scopus) -
A Phase 2 Clinical Trial of Trametinib and Low-Dose Dabrafenib in Patients with Advanced Pretreated NRASQ61R/K/L Mutant Melanoma (TraMel-WT)
Awada, G., Schwarze, J. K., Tijtgat, J., Fasolino, G., Everaert, H. & Neyns, B., 1 May 2021, In : Cancers (Basel). 13, 9, 13 p., 2010.Research output: Contribution to journal › Article
Open AccessFile34 Downloads (Pure) -
Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial
Duerinck, J., Schwarze, J. K., Awada, G., Tijtgat, J., Vaeyens, F., Bertels, C., Geens, W., Klein, S., Seynaeve, L., Cras, L., D'Haene, N., Michotte, A., Caljon, B., Salmon, I., Bruneau, M., Kockx, M., Van Dooren, S., Vanbinst, A-M., Everaert, H., Forsyth, R. & 1 others, , Jun 2021, In : Journal for immunotherapy of cancer. 9, 6, 11 p., e002296.Research output: Contribution to journal › Article
3 Citations (Scopus) -
S2-106 Talimogene laherparepvec (T-VEC)-induced tumor oncolysate as a source of tumor antigens and maturation factors for blood-isolated myeloid dendritic cells
Tijtgat, J., De Munck, J., Dufait, I., Schwarze, J. K., Breckpot, K., Neyns, B., Aerts, J. & Tuyaerts, S., 11 May 2021.Research output: Unpublished contribution to conference › Poster
File3 Downloads (Pure)
Activities
- 1 Talk or presentation at a conference
-
A phase I clinical trial on intratumoral injection of autologous CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec (T-VEC) in patients with advanced pretreated melanoma
Julia Katharina Schwarze (Presenter), Jens Tijtgat (Contributor), Gil Awada (Contributor), Louise Cras (Contributor), Inès Dufait (Contributor), Ramses Forsyth (Contributor), Sandra Tuyaerts (Contributor), Bart Neyns (Contributor)17 Sep 2021Activity: Talk or presentation › Talk or presentation at a conference
Thesis
-
IMMUNOGENIC CELL DEATH IN ONCOLYTIC VIROTHERAPY: T-VEC in the treatment of cutaneous melanoma
Author: Tijtgat, J., 2019Student thesis: Master's Thesis